UK Clinical Vaccine Network Conference 2023

Bringing together and showcasing the work of the UK clinical vaccine community, to facilitate co-operation and collaborate on future challenges.

Register now

logo as a gif

We are now accepting registrations and sponsor requests for CVNUK 2023, a hybrid event held at the Royal College of Physicians, Liverpool. If you would like to attend, please head to the registrations section and select your package.

Interested in supporting the event? We have a number of sponsorship packages available that can be tailored to your needs. To find out more please contact: Harry Whitworth

If you wish to submit an abstract for consideration at the conference, please contact: Beth Turner. The best poster will receive a £100 cash prize, and a complimentary registration to the following year’s conference.

2022’s Clinical Vaccine Network Conference was held in person at the Royal College of Physicians, London.

Although the conference has now ended, our virtual conferencing platform is still live and hosts recordings for all sessions in addition to downloadable posters. We encourage anyone interested in attending 2023’s conference to register for our On-Demand 2022 conference and view the sessions available.

Keep up to date by connecting with us on twitter: @CVN_UK

Seqirus sponsored the 2022 conference, but has had no input into the arrangements or the content except the session on “Improving Influenza Vaccine Uptake” which has specifically been sponsored and arranged by Seqirus.

To view the recordings from the online UK Clinical Vaccine Network Conference held in 2020 please click here Clinical Vaccines Network Virtual Conference 2020

Dr Christopher Green

Dr Christopher Green works as a Senior Clinical Lecturer and NHS Consultant in Infectious Diseases. His main research interest is respiratory syncytial virus (RSV) and the ongoing challenge to develop a safe and effective vaccine to prevent severe disease caused by RSV infection. His other research interests include measures to reduce antimicrobial resistance, translational stage/phase I or II clinical trials of novel vaccines, and has worked on human challenge studies for enteric fever in the past.